Amgen Inc. has opted out of a collaborative agreement with Bind Therapeutics Inc., a company developing tiny particles that adhere to medicines and help the drugs circulate longer in the bloodstream and enter cells...

Subscribe to get the full story.


Are you a subscriber? Sign In